Celyad bounces back from heart study flop to ink a $312M I/O deal with Ono

Just a few days af­ter its stem cell ther­a­py for dam­aged hearts flunked a mid-stage study, Bel­gium’s Celyad is back with a Japan­ese phar­ma deal for their im­muno-on­col­o­gy work.

Ono Phar­ma­ceu­ti­cal is hitch­ing its wag­on to Celyad’s twist on CAR-T tech. In ex­change for $12.5 mil­lion in cash and close to $300 mil­lion in biobuck mile­stones, Ono snags the rights to use Celyad’s $CYAD en­gi­neered cell tech to de­vel­op new can­cer ther­a­pies for Japan, Ko­rea and Tai­wan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER